Vedolizumab® Monoclonal Antibody for Inflammatory Bowel Disease:
Pharmaceutical Science Communication
Images created to explain drug's method of action to science community, and aid in FDA approval. The selective binding process was key concept distinguishing it from other anti-integrin therapies.
About Vedolizumab: Takeda's Vedolizumab is an anti-integrin therapy with a selective mechanism of action. The drug specifically targets the a4B7 integrin expressed on the surface of circulating leukocytes; which binds to a cell adhesion molecule only expressed on edothelial cells in the gastrointestinal tract. Because of it's selectivity, the drug is currently under investigation for use in primary types of inflammatory bowel disease - ulcerative colitis and Crohn's disease.